Samantha Guild News Today : Breaking News, Live Updates & Top Stories | Vimarsana

The FDA has approved a first-of-its-kind therapy that could help patients with metastatic melanoma, a rare but deadly form of skin cancer.

In exploratory analyses of results from the SWOG S1801 trial in patients with stage III-IV resectable melanoma, researchers saw a major pathologic response in more than half of surgical specimens taken from patients who had been treated with neoadjuvant (pre-operative) pembrolizumab.

<p style="text-align:start">In exploratory analyses of results from the SWOG S1801 trial in patients with stage III-IV resectable melanoma, researchers saw a major pathologic response in more than half of surgical specimens taken from patients who had been treated with neoadjuvant (pre-operative) pembrolizumab.&nbsp;These and other results of the analyses are presented as a proffered paper (Abstract LBA48) at the European Society of Medical Oncology (ESMO) Congress 2023 in Madrid, Spain, on Monday, October 23, by Sapna P. Patel, MD, chair of the SWOG melanoma committee and ...

Close to 90 percent of patients with unresectable (inoperable) desmoplastic melanoma, a rare form of skin cancer, saw their cancer improve after treatment with the immunotherapy drug pembrolizumab in a recent clinical trial. These results from the S1512 trial are being delivered in an oral presentation at the clinical trials plenary session of the 2023 annual meeting of the American Association for Cancer Research (AACR) in Orlando, Florida, on April 16th.